Skip to content

Psilocybin: all studies

Page 174 of 440: studies 1,731 to 1,740 of 4,400, newest first. Back to the psilocybin overview

Research

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience

European Neuropsychopharmacology January 22, 2016 Thomas Pokorny, Katrin H. Preller, Rainer Kraehenmann et al. 148 citations

The mixed serotonin (5-HT) 1A/2A/2B/2C/6/7 receptor agonist psilocybin dose-dependently induces an altered state of consciousness (ASC) that is characterized by changes in sensory perception, mood, thought, and the sense of self. The psychological effects of psilocybin are primarily mediated by 5-HT2A receptor activation. However, accumulating evidence suggests that 5-HT1A or an interaction...

DOI: 10.1016/j.euroneuro.2016.01.005 (opens in new tab) Psilocybin Buspirone Hallucinogen 5-ht1 receptor +5

HPLC Analysis of Hallucinogenic Mushroom Alkaloids (Psilocin and Psilocybin) Applying Hydrophilic Interaction Chromatography (HILIC)

Journal of Forensic Research 2016 Júlia Nagy, Tibor Veress 12 citations

Hallucinogenic mushrooms containing psilocin and psilocybin psychoactive compounds are permanent offers on the black market palette. Reliable quantifications of psilocin and psilocybin are especially important task of forensic analysis because their results have significant effect on the hardness of judgement to be punished by the court. For quantification of psilocybin mainly HPLC procedures...

DOI: 10.4172/2157-7145.1000356 (opens in new tab) Psilocybin Hydrophilic interaction chromatography High-performance liquid chromatography Hallucinogen +1

Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts

Drug and Alcohol Dependence November 1, 2015 Albert Garcia‐romeu, Tehseen Noorani, Roland R. Griffiths et al. 6 citations

Aims: We assessed long-term (>12 months) outcomes of psilocybin-facilitated smoking cessation, and qualitatively analyzed participants’ accounts to inform potential psychological mechanisms of treatment efficacy. Methods: Fifteen individuals who completed a pilot study of psilocybin-facilitated smoking cessation were invited for a long-term follow-up. Eleven (73%) returned and were interviewed...

DOI: 10.1016/j.drugalcdep.2015.07.1130 (opens in new tab) Endocannabinoid system Cannabinoid receptor 2-arachidonoylglycerol Norepinephrine +5

Sex differences and serotonergic mechanisms in the behavioural effects of psilocin

Behavioural Pharmacology October 13, 2015 Filip Tylš, Tomáš Páleníček, Lukáš Kadeřábek et al. 86 citations

Psilocybin has recently attracted a great deal of attention as a clinical research and therapeutic tool. The aim of this paper is to bridge two major knowledge gaps regarding its behavioural pharmacology – sex differences and the underlying receptor mechanisms. We used psilocin (0.25, 1 and 4 mg/kg), an active metabolite of psilocybin, in two behavioural paradigms – the open-field test and...

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Journal of Psychopharmacology October 6, 2015 Frederick S. Barrett, Matthew W Johnson, Roland R. Griffiths 634 citations

The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by psilocybin-containing mushrooms. The rated experiences occurred on average eight years before completion of the questionnaire. The current paper validates the MEQ30 using data from experimental studies with controlled doses of psilocybin. Data...

DOI: 10.1177/0269881115609019 (opens in new tab) Psilocybin Mysticism Structural equation modeling Hallucinogen +2

[Psilocybin - public available psychodysleptic].

September 7, 2015 Karolina Dydak, Mariola Śliwińska‐mossoń, Halina Milnerowicz 5 citations

Substances of plant origin have been used to induce hallucinations for a long time, in religious ceremonies and rituals as well as in pain relief. Psilocybin and psilocin naturally occur in the fungal genus Psilocybe. Due to the psychedelic effects and relative harmlessness of these substances and the fact that they do not cause physical addiction, psilocybin and psilocin recently have been...

Psilocybin, psychological distress, and suicidality

Journal of Psychopharmacology September 1, 2015 Peter S. Hendricks, Matthew W Johnson, Roland R. Griffiths 107 citations

Hendricks et al. (2015) found that having ever used any classic psychedelic substance—namely, dimethyltryptamine (DMT), ayahuasca, lysergic acid diethylamide (LSD), mescaline, peyote or San Pedro, or psilocybin—was associated with a significantly reduced likelihood of past month psychological distress (weighted OR = . 81 (. 72–. 91)), past year suicidal thinking (weighted OR = . 86 (. 78–....

DOI: 10.1177/0269881115598338 (opens in new tab) Full text (opens in new tab) Psilocybin Psychological distress Hallucinogen Clinical psychology +1

The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity

NeuroImage: Clinical August 22, 2015 Rainer Kraehenmann, André Schmidt, Karl Friston et al. 107 citations

Stimulation of serotonergic neurotransmission by psilocybin has been shown to shift emotional biases away from negative towards positive stimuli. We have recently shown that reduced amygdala activity during threat processing might underlie psilocybin's effect on emotional processing. However, it is still not known whether psilocybin modulates bottom-up or top-down connectivity within the...

Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations

Psychopharmacology July 31, 2015 Michael Kometer, Thomas Pokorny, Erich Seifritz et al. 165 citations

RationaleDuring the last years, considerable progress has been made toward understanding the neuronal basis of consciousness by using sophisticated behavioral tasks, brain-imaging techniques, and various psychoactive drugs. Nevertheless, the neuronal mechanisms underlying some of the most intriguing states of consciousness, including spiritual experiences, remain unknown.ObjectivesTo elucidate...

Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain

Neuropharmacology July 18, 2015 Aisling Spain, Clare Howarth, Alexandre A. Khrapitchev et al. 45 citations

The development of pharmacological magnetic resonance imaging (phMRI) has presented the opportunity for investigation of the neurophysiological effects of drugs in vivo. Psilocin, a hallucinogen metabolised from psilocybin, was recently reported to evoke brain region-specific, phMRI signal changes in humans. The present study investigated the effects of psilocin in a rat model using phMRI and...